These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 8076594

  • 1. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.
    Kook YH, Adamski J, Zelent A, Ossowski L.
    EMBO J; 1994 Sep 01; 13(17):3983-91. PubMed ID: 8076594
    [Abstract] [Full Text] [Related]

  • 2. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy.
    Yu W, Kim J, Ossowski L.
    J Cell Biol; 1997 May 05; 137(3):767-77. PubMed ID: 9151680
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA.
    Mohanam S, Chintala SK, Mohan PM, Sawaya R, Lagos GK, Gokaslan ZL, Kouraklis GP, Rao JS.
    Int J Oncol; 1998 Dec 05; 13(6):1285-90. PubMed ID: 9824646
    [Abstract] [Full Text] [Related]

  • 7. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.
    Ossowski L, Clunie G, Masucci MT, Blasi F.
    J Cell Biol; 1991 Nov 05; 115(4):1107-12. PubMed ID: 1659573
    [Abstract] [Full Text] [Related]

  • 8. [Antisense RNA for urokinase receptor inhibits the invasiveness and metastasis of lung carcinoma].
    Liao J, Xu S, Tang H, Lian F, Zhu Y.
    Zhonghua Bing Li Xue Za Zhi; 2001 Oct 05; 30(5):357-60. PubMed ID: 11769733
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of colon cancer metastasis by a 3'- end antisense urokinase receptor mRNA in a nude mouse model.
    Wang Y, Liang X, Wu S, Murrell GA, Doe WF.
    Int J Cancer; 2001 Apr 15; 92(2):257-62. PubMed ID: 11291054
    [Abstract] [Full Text] [Related]

  • 11. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.
    Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Kin Y, Fuller GN, Lakka SS, Kyritsis AP, Dinh DH, Olivero WC, Gujrati M, Yung WK, Rao JS.
    Clin Cancer Res; 2001 Aug 15; 7(8):2519-26. PubMed ID: 11489835
    [Abstract] [Full Text] [Related]

  • 12. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A, Kassis J, Kharait S, Kloeker S, Manos E, Jones DA, Wells A.
    Exp Cell Res; 2004 Sep 10; 299(1):91-100. PubMed ID: 15302576
    [Abstract] [Full Text] [Related]

  • 13. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
    Gondi CS, Lakka SS, Yanamandra N, Siddique K, Dinh DH, Olivero WC, Gujrati M, Rao JS.
    Oncogene; 2003 Sep 04; 22(38):5967-75. PubMed ID: 12955075
    [Abstract] [Full Text] [Related]

  • 14. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
    Albo D, Berger DH, Rothman VL, Tuszynski GP.
    J Surg Res; 1999 Apr 04; 82(2):331-8. PubMed ID: 10090848
    [Abstract] [Full Text] [Related]

  • 15. Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
    Ahmed N, Oliva K, Wang Y, Quinn M, Rice G.
    Br J Cancer; 2003 Jul 21; 89(2):374-84. PubMed ID: 12865932
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS.
    J Biol Chem; 2005 Oct 28; 280(43):36529-40. PubMed ID: 16127174
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB.
    J Cancer Res Clin Oncol; 2000 Nov 28; 126(11):641-6. PubMed ID: 11079728
    [Abstract] [Full Text] [Related]

  • 20. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
    Yang JL, Seetoo Dq, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ.
    Int J Cancer; 2000 Sep 20; 89(5):431-9. PubMed ID: 11008205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.